In Vitro Inhibition of Staphylococcus aureus subsp. aureus (ATCC® 6538™) by Artemether-Lumefantrine Tablets: A Comparative Study of Three Dosage Strengths

Opoku Solomon1, *, Nyanor Isaac2
1 Department of Quality Control, Entrance Pharmaceuticals and Research Centre, No. 16 Okpoi Gonno, Spintex Road, Post Office Box CT 10805, Accra, Ghana
2 Sickle Pan Africa Research Consortium, Kumasi Centre for Sickle Cell Disease, Komfo Anokye Teaching Hospital, Kumasi, Ghana

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 640
Abstract HTML Views: 583
PDF Downloads: 220
ePub Downloads: 147
Total Views/Downloads: 1590
Unique Statistics:

Full-Text HTML Views: 364
Abstract HTML Views: 402
PDF Downloads: 147
ePub Downloads: 95
Total Views/Downloads: 1008

© 2018 Solomon and Isaac.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: ( This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Quality Control, Entrance Pharmaceuticals and Research Centre, No. 16 Okpoi Gonno, Spintex Road, Post Office Box CT 10805, Accra, Ghana; Tel: +233205090159; E-mail:



Antibiotics are progressively failing in the fight against infections due to S. aureus because the bacterium has an outstanding ability to acquire multi-antibiotic resistance and become resistant to most antibiotics. Multi-drug resistant S. aureus poses a major threat to the foundation upon which standard antibacterial chemotherapy stands, hence the need to consider non-antibiotic solutions to manage invasive bacterial infections. This study investigated the inhibitory activities of three dosage strengths of artemether-lumefantrine tablets against Staphylococcus aureus subsp. aureus (ATCC® 6538™) and determined the minimum concentrations of the tablets that are able to completely inhibit growth of the bacterium in vitro.


The agar dilution and broth macrodilution techniques were used to determine the susceptibility of the Staphylococcus aureus subsp. aureus (ATCC® 6538™) strain to artemether-lumefantrine 20/120mg, 40/240mg and 80/480mg tablets.


The most active inhibitor was artemether-lumefantrine 80/480mg tablet with a minimum inhibitory concentration value of 2.5mg/mL while artemether-lumefantrine 20/120mg and 40/240mg tablets exhibited moderate but equal activities against the test strain.


The study has revealed that artemether-lumefantrine, an antimalarial drug, also has anti-staphylococcal properties and inhibits S. aureus in vitro. This study presents the first report on the in vitro activity of artemether-lumefantrine tablet against S. aureus and suggests the need to consider it as an alternative in the treatment of staphylococcus infections.

Keywords: Minimum inhibitory concentrations, Multi-antibiotic resistance, Artemether-lumefantrine, Test strain, S. aureus, staphylococcus infections.